Cellular interferon-γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: Action LADA 6

Cytokine

Volumn 58, Issue 2, 2012, Pages 148-151

  Strom, Alexander ^a   Menart, Barbara ^a   Simon, Marie Christine ^a   Pham, Minh Nguyet ^a   Kolb, Hubert ^b   Roden, Michael ^a,c   Pozzilli, Paolo ^d,e   Leslie, R David G ^e   Schloot, Nanette C ^a,c,f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c University Clinic   (Germany)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Diabetes; IFN ; IL 13; LADA; T cell response

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; MITOGENIC AGENT; TETANUS TOXOID;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; LATENT AUTOIMMUNE DIABETES IN ADULT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGE OF ONSET; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED;

EID: 84859214847     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.01.002     Document Type: Article

References (25)

1. Zimmet P.Z. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995, 18:1050-1064.
2. Irvine W.J., Gray R.S., McCallum C.J. Pancreatic islet-cell antibody as a marker for asymptomatic and latent diabetes and prediabetes. The Lancet 1976, 308:1097-1102.
3. Kobayashi T., Tamemoto K., Nakanishi K., Kato N., Okubo M., Kajio H., et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993, 16:780-788.
4. Cervin C., Lyssenko V., Bakhtadze E., Lindholm E., Nilsson P., Tuomi T., et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008, 57:1433-1437.
5. Andersen M.K., Lundgren V., Turunen J.A., Forsblom C., Isomaa B., Groop P.H., et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35years. Diabetes Care 2010, 33:2062-2064.
6. Juneja R., Hirsch I.B., Naik R.G., Brooks-Worrell B.M., Greenbaum C.J., Palmer J.P. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1[frac12] diabetes in patients presenting with type 2 diabetes. Metabolism 2001, 50:1008-1013.
7. Maruyama T., Oak S., Shimada A., Hampe C.S. GAD65 Autoantibody responses in Japanese latent autoimmune diabetes in adult patients. Diabetes Care 2008, 31:1602-1607.
8. Tuomi T., Groop L.C., Zimmet P.Z., Rowley M.J., Knowles W., Mackay I.R. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993, 42:359-362.
9. Van Deutekom A.W., Heine R.J., Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 2008, 25:117-125.
10. Pham M.N., Hawa M.I., Pfleger C., Roden M., Schernthaner G., Pozzilli P., et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4. Diabetologia 2011, 54:1630-1638.
11. Zhang Y., Zhou Z.G., Yang L., Lin J., Li X., He W.M. Abnormal T cell autoimmunity against GAD65 in LADA patients. Zhonghua Yi Xue Za Zhi. 2010, 90:1963-1965.
12. Brooks-Worrell B.M., Juneja R., Minokadeh A., Greenbaum C.J., Palmer J.P. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999, 48:983-988.
13. Hawa M.I., Thivolet C., Mauricio D., Alemanno I., Cipponeri E., Collier D., et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009, 32:160-164.
14. Mannering S.I., Wong F.S., Durinovic-Belló I., Brooks-Worrell B., Tree T.I., Cilio C.M., et al. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin Exp Immunol 2010, 162:197-209.
15. Pfleger C., Meierhoff G., Kolb H., Schloot N.C. Association of T-cell reactivity with [β]-cell function in recent onset type 1 diabetes patients. J Autoimmun 2010, 34:127-135.
16. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
17. Brooks-Worrell B., Tree T., Mannering S.I., Durinovic-Bello I., James E., Gottlieb P., et al. Comparison of cryopreservation methods on T-cell responses to islet and control antigens from type 1 diabetic patients and controls. Diabet Metab Res Rev 2011, 27:737-745.
18. Dige A., Hvas C.L., Kelsen J., Deleuran B., Dahlerup J.F., Agnholt J. Ethylene-diamine-tetra-acetate (EDTA) mimics the effect of regulatory T cells in suppression assays: a potential pitfall when using AutoMACS-separated cells. J Immunol Methods 2010, 353:141-144.
19. Casey J., Sturm C. Impaired response of lymphocytes from non-insulin-dependent diabetics to staphage lysate and tetanus antigen. J Clin Microbiol 1982, 15:109-114.
20. Diepersloot R., Bouter K., Beyer W., Hoekstra J., Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 1987, 30:397-401.
21. Eibl N., Spatz M., Fischer G.F., Mayr W.R., Samstag A., Wolf H.M., et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002, 103:249-259.
22. Fabrizi F., Dixit V., Martin P., Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011, 33:815-821.
23. Pozzilli P., Arduini P., Visalli N., Sutherland J., Pezzella M., Galli C., et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987, 30:817-819.
24. Pozzilli P., Gale E., Visallil N., Baroni M., Crovari P., Frighi V., et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986, 29:850-854.
25. Wismans P.J., Van Hattum J., De Gast G.C., Bouter K.P., Diepersloot R.J.A., Maikoe T.J., et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991, 35:216-222.